French pharmaceutical giant Sanofi SA said that the US Food and Drug Administration has approved its epinephrine auto-injector that provides users with audio and written instructions about going through their treatment for allergic reaction.
Marketed under the brand name Auvi-Q, the injection contains hormone epinephrine and is the first such product to be approved by the FDA.
The company said that Auvi-Q comes with a training device, a retractable needle mechanism to limit accidental needle sticks and an alert light to inform the user when injection is complete.
"As a company committed to patient-centered care, our focus is on creating innovative solutions that make a difference in the lives of people. Auvi-Q delivers on this by offering a state-of-the-art epinephrine auto-injector device that addresses the needs of patients at risk for life-threatening allergic reactions and their caregivers", Sanofi's Anne Whitaker said.